Pay with

USD

Supports Visa, Mastercard, SEPA & more

Flexible trading, zero fees

Use your crypto for payments worldwide

Basic

Trade crypto freely

Smart access to new on-chain tokens

Magnify your profit with leverage

Convert & Auto-Invest

Trade any size with no fees and no slippage

Get exposure to leveraged positions simply

Pre-Market Trading

Trade new tokens before listing

Advanced

Trade on-chain with Gate Wallet

Smart strategies with automated trading

Follow expert trading strategies

CrossEx Trading

One margin balance, shared across platforms

OTC Bank Transfer

Deposit and withdraw fiat

OTC trades with simple RFQ

Access hundreds of perpetual contracts

One platform for global traditional assets

Event Contracts

Predict price moves and seize opportunities

Trade European-style vanilla options

Unified Account

Maximize your capital efficiency

Introduction to Futures Trading

Learn the basics of futures trading

Join events to earn rewards

Use virtual funds to practice risk-free trading

Stock CFD Derivatives

Access real US stocks and ETFs

Trade quality Hong Kong-listed stocks

Real Korean stocks and top assets

Top Japanese stocks, all in one place

High leverage, 24/7 trading

Stocks Activities

Trade Popular Stocks and Unlock Generous Airdrops

Tokenized Stocks

Backed by real stock assets

Unlock full access to global stock IPOs

Launch

Collect candies to earn airdrops

Quick staking, earn potential new tokens

Hold GT and get massive airdrops for free

Unlock full access to global stock IPOs

Trade on-chain assets and earn airdrops

Earn futures points and claim airdrop rewards

Investment

One-stop digital asset wealth management

Trade & earn at the same time

Earn interest with idle tokens

Stake cryptos to earn in PoS products

Auto-invest on a regular basis

Dual Investment

Profit from market volatility

Earn rewards with flexible staking

Limited-time 11% APR on USDT

Top-tier quant strategies

Earn reliable returns from Treasury RWAs

Pledge one crypto to borrow another

One-stop lending hub

Post, share, and explore crypto trends

Live crypto market analysis

Chat with crypto traders

What is happening in crypto

Crypto guides and educational resources

Crypto insights and industry updates

In-depth research and market analysis

More

Promotions

Activity Center

Participate in activities to earn rewards

Invite friends to earn referral rewards

Affiliate Program

Earn exclusive commission rewards

Grow influence and earn airdrops

Real-time platform updates

Huge fee discounts

Asset Management

One‑stop asset management solution

Enterprise digital asset solutions

Developers (API)

Connects to the Gate application ecosystem

Generous API rebate mechanisms

Trade on TradingView

Elevate your trading experience

AI

Your all-in-one conversational AI partner

Use Gate AI directly in your social App

Gate Blue Lobster, ready to go

Gate for AI Agent

AI infrastructure, Gate MCP, Skills, and CLI

Gate Skills Hub

From office tasks to trading, the all-in-one skill hub makes AI even more useful.

Others

Find FAQs and help guides

Grow with the champions

Proof of Reserves

Gate promises 100% proof of reserves

Keep your assets secure

Regulatory Licenses, Registrations, and Approvals

Rongchang Bio responds to Pfizer's $200 million impairment of Vidisutuximab: Pfizer's conclusion is based on market competition environment.

GoldenOctober2024

2025-02-07 10:42:13

On February 7th, Jinshi Data reported that Rongchang Biology responded to the reporter's inquiry about the devaluation of its vedolizumab (RC48) by its partner Pfizer, which amounted to a reduction of 200 million US dollars. Rongchang Biology stated that this devaluation is due to changes in the market competitive environment compared to the time of the transaction, and some indications for vedolizumab have not progressed as expected, resulting in a decrease in expected value compared to the transaction time. This conclusion was made by Pfizer based on its judgment of the market competitive environment. Previously, in August 2021, Rongchang Biology authorized the overseas rights of its HER2ADC (antibody-drug conjugate) vedolizumab to ADCleading company Seagen. In 2023, Seagen was acquired by Pfizer. Currently, Pfizer is advancing the indication of vedolizumab for urothelial carcinoma overseas.

Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.

Comment

0/400

No comments